Sacubitril/Valsartan (ARNI)

Efficacy and Safety of Sacubitril/Valsartan in the Management of Heart Failure with Reduced Ejection on Fraction on and Chronic Kidney Disease: A Systema c Review and Meta-Analysis

by Prateek Chopra | May 23, 2026 | Cardiology Conferences | ESC-HF 2026 Patients with heart failure with reduced ejection fraction (HFrEF) and advanced chronic kidney disease (CKD) have limited therapeutic options and poor prognosis. Although sacubitril/valsartan has improved outcomes in HFrEF, major trials excluded patients with CKD stage 4 or higher, leaving uncertainty regarding its efficacy and safety in this […]

Efficacy and Safety of Sacubitril/Valsartan in the Management of Heart Failure with Reduced Ejection on Fraction on and Chronic Kidney Disease: A Systema c Review and Meta-Analysis Read Post »

Leave a Comment / ESC-HF Day 2 / bluetree.healthcare@gmail.com / July 30, 2026 / Cardiorenal Syndrome, Chronic Kidney Disease (CKD), Heart Failure Hospitalization, Heart Failure with Reduced Ejection Fraction (HFrEF), Sacubitril/Valsartan (ARNI)

Effect of Sacubitril/Valsartan and SGLT2 Inhibitors on Echocardiographic Responseand Clinical Outcomes A er Cardiac Resynchroniza on Therapy: Insights froma Real-world Cohort

by Prateek Chopra | May 23, 2026 | Cardiology Conferences | ESC-HF 2026 Cardiac resynchronization therapy (CRT) is recommended for symptomatic heart failure (HF) patients with prolonged QRS duration and reduced left ventricular ejection fraction (LVEF), although pivotal CRT trials predated widespread use of angiotensin receptor-neprilysin inhibitors (ARNI) and sodium-glucose co-transporter-2 inhibitors (SGLT2i). This study evaluated whether contemporary HF therapy influences

Effect of Sacubitril/Valsartan and SGLT2 Inhibitors on Echocardiographic Responseand Clinical Outcomes A er Cardiac Resynchroniza on Therapy: Insights froma Real-world Cohort Read Post »

Leave a Comment / ESC-HF Day 2 / bluetree.healthcare@gmail.com / July 30, 2026 / Cardiac Resynchronization Therapy (CRT), Guideline-Directed Medical Therapy (GDMT), Heart Failure with Reduced Ejection Fraction (HFrEF), Sacubitril/Valsartan (ARNI), SGLT2 Inhibitors

Phenotypic Clusters and Sacubitril/Valsartan in Heart Failure with PreservedEjec on Frac on: A PARAGON-HF Substudy

by Prateek Chopra | May 18, 2026 | Cardiology Conferences | ESC-HF 2026 Heart Failure with preserved ejection fraction (HFpEF) is a clinically heterogeneous syndrome with substantial variability in patient characteristics, prognosis, and therapeutic response. Despite advances in HF management, treatment outcomes in HFpEF remain inconsistent, likely reflecting differences in underlying pathophysiological mechanisms across patient subgroups. Machine learning–based phenotyping has emerged

Phenotypic Clusters and Sacubitril/Valsartan in Heart Failure with PreservedEjec on Frac on: A PARAGON-HF Substudy Read Post »

Leave a Comment / ESC-HF Day 1 / bluetree.healthcare@gmail.com / July 29, 2026 / Heart Failure with Preserved Ejection Fraction (HFpEF), Machine Learning in Cardiology, PARAGON-HF Trial, Precision Heart Failure Medicine, Sacubitril/Valsartan (ARNI)

PRAISE-MR – ARNI in HFpEF with Secondary MR

by Prateek Chopra | May 17, 2026 | Cardiology Conferences | ESC-HF 2026 Atrial functional MR (AFMR) in HFpEF is characterized by preserved LV function with left atrial enlargement and mitral annular dilatation, differing from ventricular SMR. Although randomized AFMR-specific trials have been lacking, emerging evidence with ARNI, SGLT2i, ARBs, beta-blockers, CRT, and M-TEER suggests AFMR is a potentially treatable condition.

PRAISE-MR – ARNI in HFpEF with Secondary MR Read Post »

Leave a Comment / ESC-HF Day 1 / bluetree.healthcare@gmail.com / July 29, 2026 / Atrial Functional Mitral Regurgitation (AFMR), Heart Failure with Preserved Ejection Fraction (HFpEF), Mitral Regurgitation Management, PRAISE-MR Trial, Sacubitril/Valsartan (ARNI)